Phase 2 Thyroid Cancer Trial, Terminated

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• You have been diagnosed with Anaplastic Thyroid Cancer (ATC), confirmed by a tissue biopsy (not just a fine needle aspiration alone).
• A central laboratory review of your cancer diagnosis is required for the study, though it does not have to be completed before you start treatment.
• You may still be eligible if your cancer started as a different type of thyroid cancer (differentiated thyroid cancer) but has an ATC component, as long as the measurable disease is consistent with ATC.
• You have had prior chemotherapy (before or after surgery, or to manage advanced disease) for ATC.
• You have at least one tumor that can be measured by CT or MRI scan, meeting specific size requirements set by the study team.
• If you have had cancer spread to the brain, you may still qualify if you completed brain treatment (radiation or surgery) at least one month ago, are not on steroids, and have been stable with no symptoms since then.
• Side effects from any previous chemotherapy or radiation have mostly resolved, and any surgical wounds have healed.
• You are in good enough general health to carry out daily activities with little or no limitation (confirm with trial site).
• Your blood pressure is at or below 140/90 mmHg at the time of screening, with or without blood pressure medication, and your medication has not changed in the week before starting treatment.
• Your kidneys are working well enough, based on a blood test result (confirm with trial site).
• Your blood counts (white blood cells, red blood cells, and platelets) meet the minimum levels required by the study (confirm with trial site).
• Your blood clotting is within an acceptable range, based on a standard blood test (confirm with trial site).
• Your liver is functioning well enough, based on blood test results (confirm with trial site).
• You are willing and able to give written consent and follow all parts of the study plan.

Who may not be able to join:

• You have only differentiated thyroid cancer or medullary thyroid cancer, without an ATC component.
• You are newly diagnosed and your doctors feel you are a good candidate for full combined treatment including surgery and/or radiation right now.
• You have previously been treated with lenvatinib or similar targeted cancer drugs called tyrosine kinase inhibitors (TKIs), unless a low dose was used alongside radiation therapy specifically to make the radiation work better.
• You had major surgery within the 2 weeks before starting the study drug.
• You received any cancer treatment within 14 days, or any experimental treatment within 30 days, before starting the study drug.
• You had radiation therapy within 3 weeks before starting the study drug.
• You have too much protein in your urine, above the level allowed by the study (confirm with trial site).
• You have had serious heart problems — such as severe heart failure, unstable chest pain, a heart attack, a stroke, or a significant abnormal heart rhythm — within the past 6 months.
• You have a significant abnormality on a heart electrical test (ECG), including a specific measurement being too prolonged (confirm with trial site).
• You currently have an active infection that requires treatment with antibiotics or other systemic medicines.
• You have had significant coughing up of blood or tumor bleeding within the 2 weeks before starting the study drug.
• Scans show that the cancer has grown into major blood vessels.
• You have had another active cancer within the past 24 months, with some exceptions such as certain skin cancers or early-stage cervical or bladder cancer that have been fully treated.
• You are scheduled to have major surgery during the study period.
• You are pregnant or breastfeeding.
• You are a woman who could become pregnant and are not willing or able to use a highly effective form of contraception during the study and for 30 days after finishing the study drug.
• You have another serious ongoing illness (such as heart, lung, digestive, or kidney disease) that the study doctor believes could affect your safety or the study results.
• You have a known allergy or intolerance to lenvatinib or any of its ingredients.
• You have any other medical or personal condition that the study doctor believes would prevent you from safely participating.

Important: Always verify eligibility with the trial site directly before applying.